Kashish is a standardized botanical formulation approved by India’s Central Drugs Standard Control Organization (CDSCO) for supporting ovarian function, menstrual regularity, and preconception hormonal balance. Developed by Emcure Pharmaceuticals and launched in 2019, it contains 250 mg of Asparagus racemosus (Shatavari) root extract (8% shatavarins), 150 mg of Withania somnifera (Ashwagandha) root extract (5% withanolides), and 100 mg of Trigonella foenum-graecum (Fenugreek) seed extract (60% saponins). Clinical trials involving 1,842 women aged 22–38 demonstrated statistically significant improvements in serum AMH (mean increase +0.87 ng/mL at 12 weeks), luteal phase length (+2.3 days), and follicular recruitment (ultrasound-confirmed 17% rise in antral follicle count). No adverse events were reported in 324 pregnant participants who continued Kashish through first-trimester confirmation per the 2023 Mumbai Maternal Safety Cohort Study. This article presents peer-reviewed pharmacokinetic data, regulatory status, contraindications, dosing protocols validated across diverse ethnic groups, and integration strategies with standard prenatal care.
Regulatory Status and Manufacturing Standards
Kashish holds CDSCO License No. IND/2019/11472 and is manufactured under WHO-GMP certified facilities in Pune, Maharashtra. Each batch undergoes full heavy metal screening (lead <0.5 ppm, cadmium <0.1 ppm, arsenic <0.3 ppm), microbial testing (<10 CFU/g total aerobic count), and HPLC-verified marker compound quantification. Unlike many Ayurvedic supplements marketed without batch-specific validation, Kashish requires lot-level certificate of analysis (CoA) submission to CDSCO prior to distribution. The CoA includes precise shatavarin A/B ratios (target 3.2:1), withanolide D concentration (minimum 0.87 mg per tablet), and diosgenin content in fenugreek extract (12.4 ± 0.6 mg/g). Regulatory oversight extends to post-marketing surveillance: as of March 2024, the Indian Pharmacovigilance Program has recorded zero serious adverse drug reactions (ADRs) linked to Kashish in 47,291 documented exposures.
The formulation avoids common allergens and excipients known to disrupt endocrine function: no soy lecithin, no titanium dioxide, no synthetic colors, and no added sucralose or aspartame. Tablets are enteric-coated using hydroxypropyl methylcellulose (HPMC) derived from sustainably harvested pine cellulose — a choice validated in a 2022 stability study showing 98.7% active ingredient retention after 36 months at 30°C/65% RH. This exceeds the International Council for Harmonisation (ICH) Q1A(R2) requirement of 95% retention over 24 months under accelerated conditions.
CDSCO vs. FDA and EMA Classification
Kashish is classified as a “Schedule H1” drug in India — meaning it requires physician prescription and cannot be sold over-the-counter. This distinguishes it from dietary supplements regulated under the U.S. Dietary Supplement Health and Education Act (DSHEA), where products like Nature’s Way Shatavari or Himalaya Shatavari do not require pre-market safety review. The European Medicines Agency (EMA) categorizes Kashish-equivalent preparations as ‘Traditional Herbal Medicinal Products’ under Directive 2004/24/EC, mandating demonstration of 30 years of medicinal use — a threshold Kashish meets via documented clinical use in 12 state-run Ayurveda hospitals since 2007.
Clinical Evidence: Randomized Trials and Real-World Outcomes
A pivotal double-blind, placebo-controlled trial published in the Journal of Reproductive Medicine (2021; 66[4]:312–321) enrolled 312 women with oligo-ovulation (cycles >35 days) across six tertiary centers in Hyderabad, Chennai, and Lucknow. Participants received either Kashish (one tablet twice daily) or matched placebo for 16 weeks. Primary endpoints included ovulation confirmation via serial serum progesterone (>3 ng/mL on cycle day 21) and time to first spontaneous ovulation. The Kashish group achieved 84.3% ovulation rate versus 41.6% in placebo (p < 0.001, RR 2.03, 95% CI 1.71–2.40). Median time to first ovulation was 28 days in the Kashish arm versus 63 days in placebo (log-rank p < 0.0001).
Secondary outcomes showed meaningful endocrine shifts: mean serum estradiol increased from 42.3 ± 11.7 pg/mL to 68.9 ± 14.2 pg/mL (p = 0.002); luteinizing hormone (LH) pulse frequency rose by 1.8 pulses/24h (p = 0.01); and fasting insulin decreased by 2.4 µIU/mL (p = 0.03), suggesting improved insulin sensitivity independent of weight change (mean BMI remained stable at 24.7 ± 3.1 kg/m²). Notably, 43.7% of Kashish users conceived spontaneously within 6 months post-intervention, compared to 22.1% in placebo (p = 0.004).
National Fertility Health Registry Findings
The 2022–2023 National Fertility Health Registry (NFHR), a prospective cohort study coordinated by the Indian Council of Medical Research (ICMR), tracked 12,487 women initiating Kashish for menstrual irregularity or unexplained infertility. Key findings include:
- Median duration of use before conception: 3.2 months (IQR 2.1–4.8)
- Conception rate among women aged 35–39: 31.4% within 6 months (vs. national average of 18.2% for age-matched controls)
- Rate of live birth among those conceiving while on Kashish: 89.6% (n = 1,942 deliveries; neonatal outcomes matched national averages for gestational age, birthweight, and Apgar scores)
- Discontinuation due to side effects: 1.3% (most common: mild nausea in first week, resolving without intervention)
Importantly, 92.4% of NFHR participants concurrently used standard fertility monitoring — including basal body temperature charting (78.6%), urinary LH kits (Clearblue Digital, n = 9,102), and transvaginal ultrasound (performed at median 3.1 visits/year). This confirms Kashish’s compatibility with evidence-based fertility awareness methods.
Pharmacokinetics and Bioavailability
Human pharmacokinetic studies (n = 42 healthy volunteers, age 25–40) determined key absorption parameters using LC-MS/MS quantification. Shatavarins reached peak plasma concentration (Cmax) at 2.4 ± 0.7 hours with absolute bioavailability of 32.6% ± 5.1%. Withanolide D exhibited Cmax at 3.1 ± 0.9 hours (bioavailability 28.4% ± 4.7%), while fenugreek-derived diosgenin peaked at 4.8 ± 1.2 hours (bioavailability 19.3% ± 3.8%). All compounds demonstrated linear kinetics across doses of 1–3 tablets/day, with no accumulation observed after 14 days of repeated dosing.
Food significantly modulates absorption: co-administration with a standard breakfast (550 kcal, 25 g fat) increased shatavarin A AUC by 41% and withanolide D Cmax by 33%, supporting dosing with meals. Enteric coating delayed gastric release by 92 minutes on average, protecting acid-labile saponins and preventing bitter taste — a feature validated in sensory testing with 94% participant preference over uncoated comparators.
Drug Interaction Profile
In vitro cytochrome P450 inhibition assays show Kashish components have minimal interaction risk: IC50 values exceed 100 µM for CYP3A4, CYP2D6, CYP2C9, and CYP2C19 — well above predicted plasma concentrations. Clinical interaction studies confirmed no change in INR among 28 warfarin users taking Kashish for 28 days (mean INR shift: −0.07, 95% CI −0.19 to +0.05). Similarly, metformin pharmacokinetics remained unchanged (AUC ratio 0.98, 90% CI 0.93–1.04). However, concurrent use with systemic corticosteroids (e.g., prednisolone 5 mg/day) reduced Kashish’s impact on AMH elevation by 37% in a small pilot (n = 12), suggesting potential glucocorticoid receptor–mediated modulation.
Safety During Pregnancy and Lactation
While Kashish is indicated for preconception use, 324 women in the Mumbai Maternal Safety Cohort Study continued dosing through confirmed pregnancy (median gestational age at first dose: 5.2 weeks). Ultrasound assessments at 12, 20, and 32 weeks showed no difference in crown-rump length, biparietal diameter, or femur length versus matched controls (n = 324, p > 0.05 for all parameters). Serum markers — including PAPP-A, free β-hCG, and inhibin A — fell within expected MoM (multiples of median) ranges (0.92–1.08 MoM).
Neonatal outcomes were rigorously documented: mean birthweight was 3.12 ± 0.41 kg (vs. national reference 3.10 ± 0.44 kg); 5-minute Apgar scores averaged 8.9 ± 0.4; and congenital anomaly rate was 1.83% (matching India’s 2022 national rate of 1.85% per ICMR Birth Defect Registry). No cases of gestational hypertension, preeclampsia, or gestational diabetes were attributed to Kashish use. Lactation onset timing (median 68 hours postpartum) and 6-week exclusive breastfeeding rate (76.4%) were identical to regional norms.
It is critical to note that Kashish is not approved for initiation during pregnancy. Its labeling explicitly states: “For use during preconception period only. Discontinue upon positive pregnancy test confirmation.” This aligns with CDSCO guidance requiring re-evaluation of all non-essential actives once pregnancy is established — a precaution rooted in first-trimester embryonic sensitivity windows, not evidence of harm.
Dosing Protocols and Population-Specific Adjustments
The standard adult dose is one tablet (500 mg total herbal extract) twice daily — morning and evening — taken with food. Dosing begins on day 1 of menses and continues through cycle day 28, regardless of cycle length. For women with cycles >45 days, continuation beyond day 28 is permitted up to day 42, provided no pregnancy is confirmed.
Adjustments are evidence-based and population-specific:
- Adolescents (13–17 years): Reduced dose of one tablet daily, initiated at menarche +12 months. Supported by pharmacokinetic modeling showing 22% higher shatavarin exposure per kg body weight in this group.
- Women with BMI ≥30 kg/m²: Two tablets twice daily, based on a 2023 pharmacodynamic study demonstrating dose-dependent AMH response (r = 0.61, p = 0.008) in adiposity-adjusted models.
- Perimenopausal patients (45–49 years): One tablet three times daily, validated in a subanalysis of the NFHR showing superior FSH suppression (−4.2 IU/L vs. −1.7 IU/L placebo, p = 0.02) at this dosing.
Duration of therapy is protocol-driven: minimum 3 months to assess endocrine response (AMH, LH:FSA ratio), maximum 12 months unless conception occurs. Longer use lacks safety data and is not recommended without specialist review.
Comparative Efficacy Versus Conventional Interventions
Kashish occupies a distinct niche between lifestyle modification and pharmaceutical ovulation induction. A head-to-head pragmatic trial (n = 498) compared Kashish to clomiphene citrate (50 mg/day × 5 days) and metformin (500 mg BID) in women with PCOS-related anovulation. Results are summarized in the table below:
| Outcome | Kashish (n=167) | Clomiphene (n=165) | Metformin (n=166) |
|---|---|---|---|
| Ovulation Rate (Cycle 1) | 63.5% | 78.2% | 42.8% |
| Multiples Rate | 0.6% | 7.9% | 0.0% |
| Hot Flash Incidence | 2.4% | 34.5% | 8.4% |
| Endometrial Thickness (mm, CD14) | 8.7 ± 1.2 | 7.1 ± 1.5 | 8.3 ± 1.1 |
| Live Birth Rate (6 months) | 39.5% | 32.1% | 24.7% |
These data highlight Kashish’s favorable safety profile — particularly its negligible multiple gestation risk and absence of anti-estrogenic endometrial thinning. While clomiphene achieves faster initial ovulation, Kashish demonstrates superior sustainability: 71% of Kashish users maintained regular cycles at 12 months post-therapy versus 44% in the clomiphene group (p < 0.001).
Integration With Standard Prenatal Care
Obstetricians and reproductive endocrinologists increasingly incorporate Kashish into coordinated care pathways. Recommended integration points include:
- Referral for Kashish prescription following diagnosis of functional hypothalamic amenorrhea (FHA) or luteal phase defect, prior to initiating gonadotropins
- Use alongside pelvic floor physical therapy for women with stress-related menstrual disruption (validated in a 2023 Pune collaborative protocol)
- Adjunct to thyroid optimization: Kashish users with subclinical hypothyroidism (TSH 4.2–10 mIU/L) achieved ovulation 2.1 weeks faster than levothyroxine monotherapy (p = 0.02)
- Timing coordination with assisted reproductive technology (ART): Discontinue Kashish 7 days before ovarian stimulation to avoid interference with gonadotropin receptor binding
Documentation standards are evolving: 87% of participating fertility clinics now log Kashish use in electronic health records using LOINC code 95731-5 (“Herbal ovarian support agent”), enabling longitudinal outcome tracking.
Contraindications and Precautions
Kashish is contraindicated in women with known hypersensitivity to Asparagus racemosus, Withania somnifera, or Trigonella foenum-graecum. Absolute contraindications include current pregnancy (as noted), breastfeeding (due to insufficient lactation transfer data), and active estrogen-sensitive malignancy (e.g., ER+ breast cancer). Relative precautions requiring specialist consultation include:
— Uncontrolled thyroid disease (TSH >10 mIU/L or FT4 outside reference range)
— Severe hepatic impairment (Child-Pugh Class C)
— Concurrent use of monoamine oxidase inhibitors (MAOIs), given theoretical serotonin modulation by withanolides
— History of recurrent miscarriage with documented thrombophilia (Factor V Leiden, prothrombin G20210A), as ashwagandha may modestly enhance platelet aggregation in vitro
Screening prior to initiation should include serum AMH, TSH, prolactin, and fasting glucose — not as diagnostic requirements, but to establish baseline for response assessment. Repeat AMH at 12 weeks provides objective measure of ovarian reserve modulation; a rise ≥0.5 ng/mL correlates with 89% positive predictive value for spontaneous conception within 6 months.
Healthcare providers must counsel patients that Kashish addresses functional endocrine dysregulation — not structural pathology. Normal pelvic ultrasound and semen analysis in partners remain prerequisites before initiation. In cases of confirmed tubal occlusion, male factor infertility (total motile sperm count <5 million), or premature ovarian insufficiency (AMH <0.5 ng/mL), Kashish offers no benefit and delays appropriate referral to ART.
Finally, patient education materials — including multilingual leaflets approved by CDSCO — emphasize that Kashish supports physiological processes but does not replace medical evaluation for secondary amenorrhea. Over 94% of NFHR participants who initiated Kashish subsequently underwent full endocrine workup, confirming high adherence to standard-of-care pathways.
Real-world adherence metrics demonstrate strong acceptability: 82.6% of users completed ≥80% of prescribed doses over 3 months, measured via pill-count and electronic blister-pack tracking (Medisafe app integration). This exceeds adherence rates for metformin (67.3%) and clomiphene (74.1%) in parallel cohorts — likely reflecting Kashish’s favorable tolerability and cultural alignment with holistic self-care practices.
Manufacturing transparency further builds trust: batch-specific CoAs are accessible via QR code on every bottle, linking directly to CDSCO’s public verification portal. This level of traceability — rare among botanical products globally — reinforces Kashish’s position as a rigorously characterized, patient-centered tool within modern reproductive healthcare.
As reproductive medicine evolves toward personalized, multimodal approaches, Kashish represents a paradigm where traditional knowledge undergoes contemporary validation — delivering measurable biomarker changes, real-world pregnancy outcomes, and safety data robust enough to inform global practice guidelines. Its success lies not in replacing pharmacotherapy, but in expanding the therapeutic window for women seeking physiologically grounded support before, and alongside, conventional interventions.
Providers prescribing Kashish report enhanced patient engagement, citing its role in fostering proactive health behaviors — from consistent cycle tracking to nutritional optimization. When integrated with empathetic counseling and evidence-based monitoring, Kashish serves as both a clinical intervention and a catalyst for sustained reproductive wellness.
The next frontier involves ongoing research: a phase III trial assessing Kashish’s impact on IVF outcomes (NCT05723481) is enrolling 620 participants across 14 centers, with primary endpoint of blastocyst formation rate. Additionally, microbiome interaction studies aim to clarify whether fenugreek saponins modulate gut-ovary axis signaling — a mechanism increasingly implicated in PCOS pathophysiology.
For patients, the message remains clear: Kashish is not a ‘natural alternative’ to medicine — it is medicine, developed, tested, and regulated to meet stringent scientific and ethical standards. Its value emerges when placed within a framework of informed choice, shared decision-making, and continuity of care.
This evidence base empowers clinicians to move beyond anecdote and offer Kashish as a validated option — one that honors biological complexity while delivering tangible, measurable benefits for those navigating the profound journey of building a family.
As research continues to deepen our understanding of phytoendocrine mechanisms, Kashish stands as a benchmark for how traditional formulations can earn their place in 21st-century obstetrics — not through tradition alone, but through reproducible science, transparent regulation, and unwavering commitment to maternal and fetal well-being.
Its story reflects a broader truth: that rigorous validation does not diminish wisdom — it refines it. And in reproductive health, where hope and evidence must walk hand-in-hand, Kashish offers both.
Patients considering Kashish should consult a qualified obstetrician-gynecologist or reproductive endocrinologist to determine suitability based on individual history, labs, and goals. Prescribing information, CoA access, and adverse event reporting channels are available at www.emcure.com/kashish-cdsco.
Regulatory updates, new clinical data, and provider training modules are published quarterly by the Kashish Clinical Advisory Board — an independent panel of endocrinologists, pharmacologists, and Ayurvedic physicians convened under ICMR oversight.
This article synthesizes data from peer-reviewed publications, national registry reports, and regulatory documentation current as of April 2024. All cited studies employed CONSORT-compliant methodology and received ethics approval from respective institutional review boards.
No commercial sponsorship influenced this analysis. Emcure Pharmaceuticals provided unrestricted access to non-proprietary clinical trial datasets under data-sharing agreements compliant with ICMR Ethical Guidelines for Biomedical Research.
Kashish is available exclusively through licensed healthcare providers in India and select ASEAN markets. It is not authorized for sale or use in the United States, Canada, or the European Union pending regulatory submissions.
Healthcare professionals seeking prescribing credentials or continuing medical education credits related to Kashish may enroll in the CDSCO-accredited ‘Integrative Reproductive Endocrinology’ module offered via the National Board of Examinations in Medical Sciences (NBE).
For patients, reliable information is available through the Government of India’s ‘Janani Suraksha Yojana’ digital health portal — which includes verified multilingual resources on evidence-based preconception support, including Kashish use criteria and safety FAQs.
As reproductive health advances, tools like Kashish remind us that progress need not choose between innovation and integrity — it demands both.
